HC Wainwright Has Negative Estimate for CareDx Q1 Earnings

CareDx, Inc (NASDAQ:CDNA) – Investment analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of CareDx in a research note issued on Monday, March 3rd. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.21) per share for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a “Neutral” rating and a $25.00 target price on the stock. The consensus estimate for CareDx’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx’s Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.50) EPS.

Several other analysts have also recently commented on CDNA. Stephens reiterated an “overweight” rating and issued a $40.00 price target on shares of CareDx in a research note on Thursday, February 27th. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and decreased their price target for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, CareDx presently has an average rating of “Moderate Buy” and an average price target of $31.83.

CareDx Stock Performance

CDNA opened at $20.42 on Thursday. CareDx has a fifty-two week low of $7.42 and a fifty-two week high of $34.84. The firm’s fifty day moving average is $22.67 and its 200 day moving average is $25.05. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -7.56 and a beta of 1.87.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million.

Hedge Funds Weigh In On CareDx

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP bought a new position in CareDx in the 3rd quarter worth about $27,000. Sterling Capital Management LLC raised its holdings in shares of CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock worth $27,000 after buying an additional 1,126 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new position in shares of CareDx in the third quarter worth $52,000. Tower Research Capital LLC TRC raised its holdings in shares of CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company’s stock worth $84,000 after buying an additional 3,322 shares during the last quarter. Finally, State of Wyoming acquired a new stake in shares of CareDx in the fourth quarter worth $91,000.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.